{"filing":{"accession_number":"0001193125-26-365287","cik":"0001590877","ticker":"RGNX","company_name":"REGENXBIO Inc.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-25","primary_document":"rgnx-20260825.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526365287/rgnx-20260825.htm"},"events":[{"id":29542,"run_id":27053,"accession_number":"0001193125-26-365287","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses the election of Gregory Ciongoli as a Class II director effective immediately, with appointment to the Audit Committee and Nominating and Corporate Governance Committee. While the Item 5.02 also includes the resignation of two directors (Dr. Bennett and Dr. Karabelas), the principal disclosed action centers on the appointment of a new director with specific compensation details ($550,000 initial equity award, annual retainers, and committee assignments). The appointment of a director with substantial board experience and expertise is material to investors assessing board composition and governance.","company_name":"REGENXBIO Inc.","ticker":"RGNX","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31859,"accession_number":"0001193125-26-365287","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the election of Gregory Ciongoli as a Class II director effective immediately, with appointment to the Audit Committee and Nominating and Corporate Governance Committee. While the Item 5.02 also includes the resignation of two directors (Dr. Bennett and Dr. Karabelas), the principal disclosed action centers on the appointment of a new director with specific compensation details ($550,000 initial equity award, annual retainers, and committee assignments). The appointment of a director with substantial board experience and expertise is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:58:38.051996+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31859,"accession_number":"0001193125-26-365287","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the election of Gregory Ciongoli as a Class II director effective immediately, with appointment to the Audit Committee and Nominating and Corporate Governance Committee. While the Item 5.02 also includes the resignation of two directors (Dr. Bennett and Dr. Karabelas), the principal disclosed action centers on the appointment of a new director with specific compensation details ($550,000 initial equity award, annual retainers, and committee assignments). The appointment of a director with substantial board experience and expertise is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:58:38.051996+00:00","company_name":"REGENXBIO Inc.","ticker":"RGNX","filing_date":"2026-08-25"}]}